Additionally, the 36-month beta value for EDIT is 2.11. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it as “sell.”
The public float for EDIT is 82.95M and currently, short sellers hold a 10.85% ratio of that float. The average trading volume of EDIT on June 24, 2025 was 2.08M shares.
EDIT) stock’s latest price update
The stock price of Editas Medicine Inc (NASDAQ: EDIT) has surged by 1372538 when compared to previous closing price of 2.1, but the company has seen a 0.69% gain in its stock price over the last five trading sessions. fool.com reported 2025-06-17 that The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine (EDIT 6.94%) is a promising clinical-stage company that has captured Wall Street’s attention at the forefront of the gene-editing revolution with a unique approach to CRISPR technologies.
EDIT’s Market Performance
EDIT’s stock has risen by 0.69% in the past week, with a monthly rise of 34.26% and a quarterly rise of 56.47%. The volatility ratio for the week is 7.07% while the volatility levels for the last 30 days are 6.29% for Editas Medicine Inc The simple moving average for the past 20 days is 10.00% for EDIT’s stock, with a 6.11% simple moving average for the past 200 days.
Analysts’ Opinion of EDIT
Many brokerage firms have already submitted their reports for EDIT stocks, with H.C. Wainwright repeating the rating for EDIT by listing it as a “Buy.” The predicted price for EDIT in the upcoming period, according to H.C. Wainwright is $3 based on the research report published on April 28, 2025 of the current year 2025.
EDIT Trading at 29.66% from the 50-Day Moving Average
After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.05% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EDIT starting from Parison Amy, who sale 446 shares at the price of $1.72 back on Jun 03 ’25. After this action, Parison Amy now owns 17,506 shares of Editas Medicine Inc, valued at $769 using the latest closing price.
Burkly Linda, the EVP, CHIEF SCIENTIFIC OFFICER of Editas Medicine Inc, sale 726 shares at $1.72 during a trade that took place back on Jun 03 ’25, which means that Burkly Linda is holding 69,519 shares at $1,252 based on the most recent closing price.
Stock Fundamentals for EDIT
Current profitability levels for the company are sitting at:
- -5.91 for the present operating margin
- 0.86 for the gross margin
The net margin for Editas Medicine Inc stands at -8.06. The total capital return value is set at -0.97. Equity return is now at value -140.82, with -71.37 for asset returns.
Based on Editas Medicine Inc (EDIT), the company’s capital structure generated 0.33 points at debt to capital in total, while cash flow to debt ratio is standing at -6.69.
Currently, EBITDA for the company is -231.28 million with net debt to EBITDA at 0.61. When we switch over and look at the enterprise to sales, we see a ratio of 2.43. The receivables turnover for the company is 61.13for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.08.
Conclusion
In conclusion, Editas Medicine Inc (EDIT) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
